Last updated: 11/04/2018 04:41:23

A study of GSK1325760A in Healthy Japanese Subjects

GSK study ID
AMB107623
Clinicaltrials.gov ID
NCT00424034
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Phase I study of ambrisentan – Single dose study in healthy Japanese male subjects
Trial description: To investigate the safety, tolerability, pharmacokinetics and the effect of food on pharmacokinetics after single oral administrations of GSK1325760A
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Not applicable
Allocation:
Randomized
Primary outcomes:

Adverse events Change in Clinical laboratory test Vital sign 12-lead ECG Plasma concentration Urine concentration

Timeframe: on 5 or 6 days after dosing

Secondary outcomes:
Not applicable
Interventions:
Drug: GSK1325760A
Enrollment:
32
Observational study model:
Not applicable
Primary completion date:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Healthy Subjects
Product
ambrisentan
Collaborators
Not applicable
Study date(s)
January 2007 to February 2007
Type
Interventional
Phase
1

Participation criteria

Sex
Male
Age
20 - 64 Years
Accepts healthy volunteers
Yes
  • They are considered as healthy by the investigator at screening.
  • Healthy subjects are defined as individuals who are free from clinically significant illness or disease as determined by their medical history, physical examination, clinical laboratory tests, vital sign, 12-lead ECG, immunology tests and urinary drug screening tests.
  • The subject has any clinically relevant abnormality on medical examination, vital sign, clinical laboratory test or medical history at screening in the medical opinion of the investigator or the subject has a medical history that is not considered as eligible for inclusion in this study by the investigator.
  • The subject has an allergy for any drug or idiosyncrasy. This excludes a pollen allergy without current symptoms.
Inclusion and exclusion criteria
Inclusion criteria:
  • They are considered as healthy by the investigator at screening. Healthy subjects are defined as individuals who are free from clinically significant illness or disease as determined by their medical history, physical examination, clinical laboratory tests, vital sign, 12-lead ECG, immunology tests and urinary drug screening tests.
  • They are Japanese males.
  • Aged 20 to 64 years, inclusive.
  • They have a body mass index (weight/height2) at screening in the range of 18.5 and <25.0 kg/m2 inclusive. Standard weight is in the range of 55-85 kg inclusive.
  • Blood pressure and pulse rate at screening within the normal range (systolic 90-140 mmHg, diastolic 40-90 mmHg, pulse rate 40-90bpm).
  • They have the following clinical laboratory test
  • Biochemistry (AST(GOT), ALT(GPT), ALP, LDH and gamma-GTP : within normal range at screening.
  • Haematology (RBC, Hb and Ht) below upper limit normal range at screening.
  • Normal ECG at screening (QTc value of <440msec).
  • They give their consent to be able to abstain from sexual intercourse or use condom for contraception from at screening until post-study screen.
  • They are capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
  • They are non-smokers (at least 6 months).
  • They are able to attend all visits and complete the study.
Exclusion criteria:
  • The subject has any clinically relevant abnormality on medical examination, vital sign, clinical laboratory test or medical history at screening in the medical opinion of the investigator or the subject has a medical history that is not considered as eligible for inclusion in this study by the investigator.
  • The subject has an allergy for any drug or idiosyncrasy. This excludes a pollen allergy without current symptoms.
  • The subject has participated in a clinical study or post-marketing study with an investigational or a non-investigational product or device during the previous 4 months of the first dosing.
  • The subject is concurrently participating in another clinical study or post-marketing study in which the subject is or will be exposed to an investigational or a non-investigational product or device.
  • The subject is positive for syphilis, HBs antigen, HCV antibody, HIV antibody, HTLV-1 antibody.
  • The subject is positive for urine drugs of abuse test.
  • The subject has donated a unit of blood (>400mL) within the previous 4 months or (>200mL) within the previous 1 month of screening.
  • The subject is currently taking regular (or a course of) medication (including prescribed drug, over-the-counter medication and herbal preparations). Medication nor permitted during the study must be discontinued 14 days prior to dosing.
  • The subject has a history or current conditions of drug abuse or alcoholism according to ICD10.
  • The subject has a history of regular alcohol consumption exceeding 7 drinks/week (1 drink = 350mL of beer) within 6 months of the first dosing.

Trial location(s)

No location data available.

Study documents

No study documents available.

Results overview

Study Results yet to be posted

Recruitment status
Completed
Actual primary completion date
Not applicable
Actual study completion date
2007-26-02

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website